PPLPHARMA - Swing Trade Analysis with AI Signals

Last Updated Time : 05 Nov 25, 7:43 am

Swing Trade Rating: 3.8

📈 Positive

• 📊 Price is near both DMA 50 (₹199) and DMA 200 (₹203), indicating a consolidation zone with breakout potential.
• 📈 RSI at 52.4 and MACD at 1.29 suggest neutral-to-bullish momentum.
• 📈 Volume (47.1 lakh) is significantly above 1-week average (31.7 lakh), showing strong market interest.
• 📘 PEG ratio of 1.67 and P/E of 37.0 vs industry P/E of 33.1 suggest fair valuation.
• 📈 DII holding increased by 0.64%, reflecting growing domestic institutional confidence.

⚠️ Limitation

• 📉 ROCE (12.4%) and ROE (9.74%) are moderate, indicating average capital efficiency.
• 📉 Dividend yield of 0.07% offers minimal passive income.
• 📉 FII holding declined by 0.59%, showing reduced foreign investor interest.
• 📉 PAT dropped from ₹277 Cr. to ₹113 Cr., indicating earnings volatility.

🚫 Company Negative News

• 📉 Analysts have flagged concerns over margin compression and inconsistent quarterly performance.

✅ Company Positive News

• 💊 PPLPHARMA is expanding its specialty pharma portfolio and focusing on operational efficiency.
• 📈 Despite profit drop, strong volume and institutional support suggest resilience.

🏦 Industry

• 🧬 Operates in the pharmaceutical sector, which is defensive and benefits from consistent demand and innovation.
• 📊 Industry P/E of 33.1 reflects stable growth expectations.

🧾 Conclusion

• 📈 PPLPHARMA is technically stable with strong volume and fair valuation, making it a reasonable swing trade candidate.
• 📍 Optimal entry: ₹195–₹198 (near DMA 50 and support zone).
• 🚪 Exit if held: ₹215–₹225 (near short-term resistance) unless momentum strengthens.
• ⚠️ Suitable for swing trading with moderate risk and close monitoring of earnings and institutional flows.

I can also compare PPLPHARMA’s swing setup with peers like Piramal Enterprises or GSK Pharma to refine your strategy.